United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program Agreements for aggregate $1.5 billion Accelerated ...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new stock repurchase program of up to $2 billion ...
Agreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next year SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Mar 9, 2026-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board ...
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr.Martine Rothblatt, Chairperson and Chief Executive Officer, will provide a company overview and update on Monday, March 9, 2026, ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, ...
[Audio Gap] get started. So thank you, everyone, for joining us in the room and online at TD Cowen's 46th Annual Healthcare Conference. I'm Joe Thome, one of the senior biotech analysts here on the ...
March 2 (Reuters) - United Therapeutics (UTHR.O), opens new tab said on Monday its experimental drug to treat a rare lung condition cut the risk of the disease worsening by 55% in a late-stage study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results